Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
Genetic Testing Firms Stocks$60.46
-0.01%4:00PM 11/25/2022
The list of companies include MYGN-Myriad Genetics, Inc., NVTA-Invitae Corp, NTRA-Natera Inc, DGX-Quest Diagnostics, Inc., LH-Laboratory Corp. Of America Holdings, CODX-Co-Diagnostics Inc, OCX-OncoCyte Corp, NEOG-Neogen Corp., PRPO-Precipio Inc, FLGT-Fulgent Genetics Inc, VCYT-Veracyte Inc
Latest intraday update before market close @ 18:01:14 PM 11/25/2022
Summary :
Average return is down -0.0%
Median return is up 0.4%
7 out of 10 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information


  • Genetic Testing Firms stocks down 0.0% on average while median return down -0.4% in a day
  • Genetic Testing Firms stocks down 0.2% on average while median return down -2.0% in a week
  • Genetic Testing Firms stocks up 8.5% on average while median return up 1.8% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

1 Day Return
1 Week Return
1 Month Return
PE Ratio
P/B (mrq)
P/S (ttm)
Earning Growth
Short %
Held By Institutions %
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
12.84-1.072.541.6621.4B2%94%59/\Above resistance154-0.1%
14.66-1.372.481.50374%17B9%93%63/\Above resistance151-0.0%
48.1813.835.9310.6710%1.8B5%95%66-/\Above resistance125-0.5%
2.5920.481.9B7%106%60/\Above resistance151-0.2%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $VCYT 42.7%, $NEOG 30.7%, $NVTA 12.1%, $LH 5.0%, $DGX 3.9%
  • 1M losers are : Losers for past month are $CODX -0.3%, $MYGN -2.1%, $GENE -3.2%, $FLGT -8.0%, $NTRA -18.9%
  • 1W winners are : Winners for past week are $NTRA 4.8%, $NEOG 4.2%, $LH 3.6%, $FLGT 2.8%, $DGX 2.1%
  • 1W losers are : Losers for past week are $VCYT -3.1%, $GENE -4.2%, $CODX -6.2%, $NVTA -7.3%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 24.1%, for the past 3 months is 32.6%

In the past month for a 5 days rolling window, the highest corrrelation is 45.7%, the lowest correlation is 5.3%, the latest correlation is 8.7%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 78.1% between FLGT and NVTA

The lowest correlation is -68.1% between DGX and PRPO

Stock news

    1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

    Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.

    Neogen® to Participate in the Piper Sandler 34th Annual Healthcare Conference

    Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference in New York City on Wednesday, November 30, 2022.

    Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET).

    Biotech companies Natera and Synthego are laying off a total of 163 employees

    A pair of biotechnology companies with offices on the Peninsula are cutting a combined 163 employees. Natera Inc. alerted state employment officials of its layoffs Nov. 4, the same day it notified 58 of its San Carlos-based workers that they were losing their jobs. Synthego Corp., meanwhile, alerted state authorities on Nov. 14 that it planned to cut 105 employees in Redwood City last Friday.

    New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma. The findings indicated an association between early reductions in ctDNA and longer overall survival, suggesting that traditional radiographic-based response criteria don't accurately reflect tebentafusp-related clinical activity and

    Neogen's (NEOG) Synergize Disinfectant Now Widely Available

    Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.

    Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

    TEMPLE CITY, Calif., November 17, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

    GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

    Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall care, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN). Yet, results of the Spring 202

    What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

    The latest analyst coverage could presage a bad day for Fulgent Genetics, Inc. ( NASDAQ:FLGT ), with the analysts...

    Natera Announces Pricing of Follow-On Offering

    Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price